Connection
Jeffrey Swigris to Clinical Trials, Phase II as Topic
This is a "connection" page, showing publications Jeffrey Swigris has written about Clinical Trials, Phase II as Topic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.044 |
|
|
|
-
Corte TJ, Lancaster L, Swigris JJ, Maher TM, Goldin JG, Palmer SM, Suda T, Ogura T, Minnich A, Zhan X, Tirucherai GS, Elpers B, Xiao H, Watanabe H, Smith RA, Charles ED, Fischer A. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). BMJ Open Respir Res. 2021 Dec; 8(1).
Score: 0.044